1-10 of 10
Cynthia C. Harrington
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

Andrew R. Branagan, Matthew M Lei, Clifton C Mo, Andrew J. Yee, Elizabeth K. O'Donnell, Jorge J. Castillo, Omar Nadeem, Noopur Raje, Steven P Treon, Paul G. Richardson, Rie Nakamoto-Matsubara, Kirsten Meid, Zachary S. Bernstein, Rebecca T. Lyons, Rakesh Verma, Zachary R Hunter, Maria Luisa Guerrera, Catherine A. Flynn, Jill N. Burke, Cynthia C. Harrington, Emerentia Agyemang, Marilyn T. Gammon, Kathleen J. Lively, Lisette Packer, Nora K. Horick, Shayna Sarosiek
Journal: Blood
Blood (2022) 140 (Supplement 1): 10094–10096.
https://doi.org/10.1182/blood-2022-167899
Published: 2022
Journal Articles

A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Elizabeth K. O'Donnell, Clifton C Mo, Omar Nadeem, Andrew J. Yee, Andrew R. Branagan, Jacob Laubach, Marilyn T. Gammon, Kathleen J. Lively, Lisette Packer, Cynthia C. Harrington, Emerentia Agyemang, Jacalyn Rosenblatt, Nora K. Horick, Paul G. Richardson, Noopur Raje
Journal: Blood
Blood (2022) 140 (Supplement 1): 7282–7283.
https://doi.org/10.1182/blood-2022-156328
Published: 2022
Journal Articles

A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Elizabeth K. O'Donnell, Clifton C. Mo, Andrew J. Yee, Omar Nadeem, Andrew R. Branagan, Jacob P. Laubach, Marilyn T. Gammon, Kathleen J. Lively, Lisette Packer, Cynthia C. Harrington, Emerentia Agyemang, Kerry Spillane, Brenton LaStofka, Jacalyn Rosenblatt, Noopur S. Raje, Paul G. Richardson
Journal: Blood
Blood (2021) 138 (Supplement 1): 5043.
https://doi.org/10.1182/blood-2021-146284
Published: 2021
Journal Articles

Real-World Observations and Practical Considerations of Subcutaneous Daratumumab Administration in Multiple Myeloma

E. Bridget Kim, Elizabeth O'Donnell, Andrew R. Branagan, Jill N. Burke, Cynthia C. Harrington, Emerentia Agyemang, Noopur S. Raje, Andrew J. Yee
Journal: Blood
Blood (2021) 138 (Supplement 1): 5018.
https://doi.org/10.1182/blood-2021-153751
Published: 2021
Journal Articles

Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma

Elizabeth K. O'Donnell, Yael Shapiro, Omar Nadeem, Andrew J. Yee, Jacob P. Laubach, Andrew R. Branagan, Kenneth C. Anderson, Clifton C. Mo, Nikhil C. Munshi, Irene M. Ghobrial, Adam S. Sperling, Emerentia Agyemang, Jill N. Burke, Cynthia C. Harrington, Paul G. Richardson, Noopur S. Raje, Areej El-Jawahri
Journal: Blood
Blood (2021) 138 (Supplement 1): 3044.
https://doi.org/10.1182/blood-2021-146290
Published: 2021
Journal Articles

Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma

Elizabeth K. O'Donnell, Yael Shapiro, Omar Nadeem, Andrew J. Yee, Jacob P. Laubach, Andrew R. Branagan, Kenneth C. Anderson, Clifton C. Mo, Nikhil C. Munshi, Irene M. Ghobrial, Adam S. Sperling, Emerentia Agyemang, Cynthia C. Harrington, Jill N. Burke, Paul G. Richardson, Noopur S. Raje, Areej El-Jawahri
Journal: Blood
Blood (2021) 138 (Supplement 1): 4082.
https://doi.org/10.1182/blood-2021-146342
Published: 2021
Journal Articles

Extending Dosing Intervals of Denosumab As a Maintenance Strategy in Multiple Myeloma: A Real-World Experience at a Large Academic Cancer Center

E. Bridget Kim, PharmD, Yael N. Kahn, Andrew R. Branagan, MD, Andrew J. Yee, Jill N. Burke, NP, Cynthia C. Harrington, NP, Emerentia Agyemang, NP, Noopur S. Raje, MD, Elizabeth K. O'Donnell, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13.
https://doi.org/10.1182/blood-2020-136576
Published: 2020
Journal Articles

Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma

Elizabeth K. O'Donnell, MD, Jacob P. Laubach, MD, Andrew J. Yee, MD, Robert Redd, Carol Ann Huff, MD, Frank Basile, MD, Philip M. Wade, MD, Claudia E. Paba-Prada, MD, Irene M. Ghobrial, MD, Robert L. Schlossman, MD, Jill N. Burke, NP, Cynthia C. Harrington, NP, Kathleen J. Lively, RN, Hannah Lyons, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Noopur S. Raje, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3178.
https://doi.org/10.1182/blood-2019-128000
Published: 2019
Journal Articles

A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Andrew J. Yee, MD, Jacob P. Laubach, MD, Erica L. Campagnaro, MD, Brea C. Lipe, MD, Omar Nadeem, MD, Robb S Friedman, MD, Craig E. Cole, MD, Elizabeth K. O'Donnell, MD, Giada Bianchi, MD, Andrew R. Branagan, MD, Samantha J. Shapiro, Cynthia C. Harrington, NP, Jill N. Burke, NP, Marilyn T. Gammon, RN, Kathleen J. Lively, RN, Cassandra A. Thorburn, Mason L. Mann, Jens G. Lohr, MD PhD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Noopur S. Raje, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3169.
https://doi.org/10.1182/blood-2019-124870
Published: 2019
Journal Articles

Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma

Andrew J. Yee, MD, Jacob P. Laubach, MD, Ajay K. Nooka, MD MPH, Elizabeth K. O'Donnell, MD, Edie A. Weller, PhD, Nicole R. Couture, BSN, RN, Ellen E. Wallace, BA, Jill N. Burke, NP, Cynthia C. Harrington, NP, Marie Puccio-Pick, MS, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Noopur S. Raje, MD
Journal: Blood
Blood (2015) 126 (23): 4241.
https://doi.org/10.1182/blood.V126.23.4241.4241
Published: 2015